Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of luxdegalutamide plus lutetium (177Lu) vipivotide tetraxetan in PSMA-positive metastatic castration-resistant prostate cancer
CTR20254246Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luxdegalutamide in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoints: PSA50 response, Adverse events, laboratory values, vital signs, and ECG changes and 1 more. Started Jan 2026; status: active.
02
Drugs
luxdegalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20254246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254246.